RU2008112198A - Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств - Google Patents
Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств Download PDFInfo
- Publication number
- RU2008112198A RU2008112198A RU2008112198/04A RU2008112198A RU2008112198A RU 2008112198 A RU2008112198 A RU 2008112198A RU 2008112198/04 A RU2008112198/04 A RU 2008112198/04A RU 2008112198 A RU2008112198 A RU 2008112198A RU 2008112198 A RU2008112198 A RU 2008112198A
- Authority
- RU
- Russia
- Prior art keywords
- alkylene
- alkyl
- compounds
- formula
- mono
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 2
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 35
- 125000002947 alkylene group Chemical group 0.000 claims abstract 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 23
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 21
- 125000000217 alkyl group Chemical group 0.000 claims abstract 20
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 19
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 19
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 18
- 125000003118 aryl group Chemical group 0.000 claims abstract 17
- 229910052736 halogen Inorganic materials 0.000 claims abstract 17
- 150000002367 halogens Chemical class 0.000 claims abstract 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 16
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 12
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims abstract 12
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 5
- 125000004450 alkenylene group Chemical group 0.000 claims abstract 5
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 5
- 125000005842 heteroatom Chemical group 0.000 claims abstract 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 2
- 229910052794 bromium Inorganic materials 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 239000008177 pharmaceutical agent Substances 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 1
- -1 CF2CH2CH3 Chemical group 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 230000004129 fatty acid metabolism Effects 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05021277.8 | 2005-09-29 | ||
| EP05021277 | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008112198A true RU2008112198A (ru) | 2009-10-10 |
Family
ID=35788653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008112198/04A RU2008112198A (ru) | 2005-09-29 | 2006-09-26 | Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7709481B2 (https=) |
| EP (1) | EP1931337B1 (https=) |
| JP (1) | JP2009509988A (https=) |
| KR (1) | KR20080048504A (https=) |
| CN (1) | CN101272784A (https=) |
| AR (1) | AR056095A1 (https=) |
| AU (1) | AU2006299091A1 (https=) |
| BR (1) | BRPI0617207A2 (https=) |
| CA (1) | CA2624102A1 (https=) |
| CR (1) | CR9785A (https=) |
| DO (1) | DOP2006000203A (https=) |
| EC (1) | ECSP088322A (https=) |
| IL (1) | IL190231A0 (https=) |
| MA (1) | MA29805B1 (https=) |
| NO (1) | NO20081369L (https=) |
| NZ (1) | NZ566877A (https=) |
| PE (1) | PE20070620A1 (https=) |
| RU (1) | RU2008112198A (https=) |
| TN (1) | TNSN08148A1 (https=) |
| TW (1) | TW200806658A (https=) |
| UY (1) | UY29831A1 (https=) |
| WO (1) | WO2007039177A2 (https=) |
| ZA (1) | ZA200801629B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| AU2009231906A1 (en) * | 2008-03-31 | 2009-10-08 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| BRPI0920767B1 (pt) * | 2008-10-01 | 2018-07-17 | Bayer Intellectual Property Gmbh | tiazóis substituídos por heterociclila como agentes protetores de cultura, seus usos e seus processos de preparação, composições e seu processo de preparação, e método para combate a fungos nocivos fitopatogênicos |
| BRPI0923366A2 (pt) | 2008-12-11 | 2019-09-24 | Bayer Cropscience Ag | éteres e hodrazonas de oxima de tiazolila como agentes protetors de culturas. |
| EP2198710A1 (de) | 2008-12-19 | 2010-06-23 | Bayer CropScience AG | Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze |
| NZ596467A (en) * | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| JP5909185B2 (ja) | 2009-10-01 | 2016-04-26 | シマベイ セラピューティクス， インコーポレーテッド | 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩 |
| NZ599099A (en) | 2009-10-08 | 2013-05-31 | Sanofi Sa | Phenyloxadiazole derivatives as pgds inhibitors |
| JP5960683B2 (ja) | 2010-04-28 | 2016-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 殺真菌剤としてのケトヘテロアリールピペリジンおよび−ピペラジン誘導体 |
| JP5847813B2 (ja) | 2010-06-23 | 2016-01-27 | シマベイ セラピューティクス， インコーポレーテッド | ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物 |
| EP2532233A1 (en) | 2011-06-07 | 2012-12-12 | Bayer CropScience AG | Active compound combinations |
| SI2841437T1 (sl) | 2012-04-26 | 2017-09-29 | Bristol-Myers Squibb Company | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
| EP2855489B1 (en) | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| SG11201406759YA (en) | 2012-04-26 | 2014-11-27 | Bristol Myers Squibb Co | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| AU2017305392A1 (en) | 2016-08-03 | 2019-02-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| AU2381397A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| ES2199366T3 (es) | 1996-12-31 | 2004-02-16 | Dr. Reddy's Laboratories Ltd. | Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas. |
| JP4253126B2 (ja) | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ調節剤 |
| US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| PL350669A1 (en) | 1999-03-29 | 2003-01-27 | Hoffmann La Roche | Glucokinase activators |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| PL351470A1 (en) | 1999-04-28 | 2003-04-22 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| AU770870B2 (en) * | 1999-06-18 | 2004-03-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| KR20020033778A (ko) | 1999-09-01 | 2002-05-07 | 로버트 흐라이탁, 미쉘 베스트 | 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도 |
| GB9921684D0 (en) | 1999-09-15 | 1999-11-17 | Zeneca Ltd | Assays |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| AU5227001A (en) | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Hydantoin-containing glucokinase activators |
| MXPA02010745A (es) | 2000-05-03 | 2003-03-10 | Hoffmann La Roche | Activadores de glucocinasa heteroaromaticos de alquinil-fenilo. |
| WO2001085707A1 (en) | 2000-05-08 | 2001-11-15 | F. Hoffmann-La Roche Ag | Para-amine substituted phenylamide glucokinase activators |
| DK1282611T3 (da) | 2000-05-08 | 2005-02-14 | Hoffmann La Roche | Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer |
| DE60111534T2 (de) | 2000-07-20 | 2006-05-11 | F. Hoffmann-La Roche Ag | Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren |
| US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| DE60117059T2 (de) | 2000-12-06 | 2006-10-26 | F. Hoffmann-La Roche Ag | Kondensierte heteroaromatische glucokinaseaktivatoren |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| DE10102322A1 (de) | 2001-01-19 | 2002-07-25 | Merck Patent Gmbh | Phenylderivate |
| TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
| GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| BRPI0211844B8 (pt) * | 2001-08-10 | 2021-05-25 | Nippon Chemiphar Co | composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| AU2002333456B2 (en) | 2001-08-31 | 2008-07-17 | Sanofi-Aventis Deutschland Gmbh | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators |
| US7205321B2 (en) | 2001-11-15 | 2007-04-17 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
| US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
| PL370989A1 (en) | 2001-12-21 | 2005-06-13 | Novo Nordisk A/S | Amide derivatives as gk activators |
| EP1480957A1 (en) | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
| EP1496052B1 (en) | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| IL164249A0 (en) | 2002-04-11 | 2005-12-18 | Aventis Pharma Gmbh | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use |
| EP1501815B1 (en) | 2002-04-26 | 2006-11-22 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| AU2003235307A1 (en) | 2002-05-16 | 2003-12-02 | Banyu Pharmaceutical Co., Ltd. | Crystal of glucokinase protein, and method for drug design using the crystal |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| MXPA05000053A (es) | 2002-07-12 | 2005-04-08 | Aventis Pharma Gmbh | Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos. |
| PL375149A1 (en) | 2002-10-03 | 2005-11-28 | F.Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (gk) activators |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2003294376A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| DE60336850D1 (en) | 2003-01-06 | 2011-06-01 | Lilly Co Eli | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| US7262196B2 (en) | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| NZ540791A (en) | 2003-02-13 | 2009-09-25 | Banyu Pharma Co Ltd | Novel 2-pyridinecarboxamide derivatives |
| DE10308352A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308356A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308351A1 (de) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308354A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| JPWO2004080943A1 (ja) | 2003-03-11 | 2006-06-08 | 小野薬品工業株式会社 | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| DE602004002394T2 (de) | 2003-04-17 | 2007-09-13 | Kalypsys, Inc., San Diego | (3-{3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino]-propoxy}-phenyl)-essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen |
| CA2524436A1 (en) | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
| GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| US20070054902A1 (en) | 2003-12-02 | 2007-03-08 | Shionogi & Co., Ltd. | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists |
| GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| CA2547785A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
| AU2004308332B2 (en) | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| BRPI0418212A (pt) | 2003-12-29 | 2007-04-27 | Banyu Pharma Co Ltd | composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade |
| BRPI0506662B8 (pt) | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| DE602004007693T2 (de) | 2004-01-06 | 2008-06-05 | Janssen Pharmaceutica N.V. | (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas |
| AU2005209365A1 (en) | 2004-01-31 | 2005-08-11 | Sanofi-Aventis Deutschland Gmbh | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments |
| DE102004006325A1 (de) | 2004-02-10 | 2005-08-25 | Bayer Healthcare Ag | Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung |
| KR20070007104A (ko) | 2004-02-18 | 2007-01-12 | 아스트라제네카 아베 | 화합물 |
| BRPI0507746A (pt) | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto |
| SI1751131T1 (sl) | 2004-03-10 | 2009-04-30 | Janssen Pharmaceutica Nv | MTP inhibirajoči aril piperidini ali piperazini substituirani s 5-členskimi heterocikli |
| US7687502B2 (en) | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| RU2375358C2 (ru) * | 2004-04-01 | 2009-12-10 | Авентис Фармасьютикалз, Инк. | 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение |
| BRPI0508180A (pt) | 2004-04-01 | 2007-08-07 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste |
| DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
| EP1736467A4 (en) | 2004-04-06 | 2009-07-01 | Dainippon Sumitomo Pharma Co | NEW SULFONIC ACID AMID DERIVATIVE |
| MXPA06012008A (es) | 2004-04-21 | 2007-01-25 | Prosidion Ltd | Compuestos de amida tri(ciclo) sustituidos. |
| CA2565211A1 (en) | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| US20080026987A1 (en) | 2004-06-17 | 2008-01-31 | Novo Nordisk A/S | Use of Liver-Selective Glucokinase Activators |
| GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| DE102004039533B4 (de) | 2004-08-14 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE102004039509B4 (de) | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102004039532B4 (de) | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| EP1794159B1 (en) | 2004-09-11 | 2012-08-01 | Sanofi-Aventis Deutschland GmbH | 7-azaindoles and their use as ppar agonists |
| DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
-
2006
- 2006-09-26 CA CA002624102A patent/CA2624102A1/en not_active Abandoned
- 2006-09-26 JP JP2008532647A patent/JP2009509988A/ja not_active Abandoned
- 2006-09-26 EP EP06792251.8A patent/EP1931337B1/en active Active
- 2006-09-26 KR KR1020087007393A patent/KR20080048504A/ko not_active Withdrawn
- 2006-09-26 WO PCT/EP2006/009303 patent/WO2007039177A2/en not_active Ceased
- 2006-09-26 AU AU2006299091A patent/AU2006299091A1/en not_active Abandoned
- 2006-09-26 RU RU2008112198/04A patent/RU2008112198A/ru not_active Application Discontinuation
- 2006-09-26 BR BRPI0617207-5A patent/BRPI0617207A2/pt not_active IP Right Cessation
- 2006-09-26 NZ NZ566877A patent/NZ566877A/en not_active IP Right Cessation
- 2006-09-26 CN CNA2006800359361A patent/CN101272784A/zh active Pending
- 2006-09-27 TW TW095135658A patent/TW200806658A/zh unknown
- 2006-09-27 DO DO2006000203A patent/DOP2006000203A/es unknown
- 2006-09-27 AR ARP060104223A patent/AR056095A1/es not_active Application Discontinuation
- 2006-09-27 PE PE2006001170A patent/PE20070620A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29831A patent/UY29831A1/es not_active Application Discontinuation
-
2008
- 2008-02-19 ZA ZA200801629A patent/ZA200801629B/xx unknown
- 2008-02-29 CR CR9785A patent/CR9785A/es not_active Application Discontinuation
- 2008-03-14 NO NO20081369A patent/NO20081369L/no not_active Application Discontinuation
- 2008-03-17 IL IL190231A patent/IL190231A0/en unknown
- 2008-03-24 MA MA30781A patent/MA29805B1/fr unknown
- 2008-03-26 US US12/055,780 patent/US7709481B2/en not_active Expired - Fee Related
- 2008-03-27 EC EC2008008322A patent/ECSP088322A/es unknown
- 2008-03-28 TN TNP2008000148A patent/TNSN08148A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY29831A1 (es) | 2007-04-30 |
| ECSP088322A (es) | 2008-04-28 |
| NO20081369L (no) | 2008-05-28 |
| EP1931337B1 (en) | 2013-10-23 |
| US7709481B2 (en) | 2010-05-04 |
| WO2007039177A2 (en) | 2007-04-12 |
| MA29805B1 (fr) | 2008-09-01 |
| WO2007039177B1 (en) | 2007-11-01 |
| CA2624102A1 (en) | 2007-04-12 |
| PE20070620A1 (es) | 2007-07-10 |
| EP1931337A2 (en) | 2008-06-18 |
| CN101272784A (zh) | 2008-09-24 |
| CR9785A (es) | 2008-05-21 |
| NZ566877A (en) | 2010-05-28 |
| AU2006299091A1 (en) | 2007-04-12 |
| TW200806658A (en) | 2008-02-01 |
| WO2007039177A3 (en) | 2007-09-07 |
| US20080261979A1 (en) | 2008-10-23 |
| DOP2006000203A (es) | 2007-06-30 |
| IL190231A0 (en) | 2008-11-03 |
| JP2009509988A (ja) | 2009-03-12 |
| AR056095A1 (es) | 2007-09-19 |
| ZA200801629B (en) | 2009-03-25 |
| TNSN08148A1 (en) | 2009-07-14 |
| BRPI0617207A2 (pt) | 2011-07-19 |
| KR20080048504A (ko) | 2008-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008112198A (ru) | Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств | |
| RU2008112202A (ru) | Производные фенил-[1,2,4]-оксадиазол-5-она с фенильной группой, способы их получения и их применение в качестве фармацевтических средств | |
| RU2010154279A (ru) | Аннелированные n-гетероциклические сульфонамиды с оксадиазолоновой концевой группой, способы их получения и их применение в качестве фармацевтических препаратов | |
| RU2424240C2 (ru) | Антибактериальные производные пиперидина | |
| ES2378776T3 (es) | Derivado de ácido aminocarboxílico y uso medicinal del mismo | |
| RU2012134351A (ru) | Способы лечения дисфункции мейбомиевых желез | |
| EP2620429A1 (en) | Hydroxylamine compounds and methods of their use | |
| FR2932483A1 (fr) | Composes utiles pour le traitement des cancers. | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| TW201623223A (zh) | 巨大戟萜醇－３－醯化物ｉｉｉ及巨大戟萜醇－３－胺基甲酸酯化物 | |
| RU2008116581A (ru) | Сульфонамидные производные, как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| RU2009121775A (ru) | Пиридильное неароматическое азот-содержащее гетероцикло-1-карбоксилатное производное | |
| JP2004504388A5 (https=) | ||
| JP2018502101A5 (https=) | ||
| HK1254129A1 (zh) | 给予谷氨酰胺酶抑制剂的方法 | |
| RU2005129999A (ru) | Диарилциклоалкильные производные, способы их получения и их применение в качестве лекарственного средства | |
| AR029151A1 (es) | Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene | |
| KR20150140419A (ko) | 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드 | |
| DE69013511T4 (de) | Aminosäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
| RU2017115726A (ru) | Ингибиторы лизин-специфичного гингипаина | |
| RU2005130002A (ru) | Производные 3-метил-2-(2-фенилоксазол-4-илметокси)циклогексанкарбониламино)масляной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза | |
| EP1230230A1 (de) | Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel | |
| RU2006138426A (ru) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой | |
| JP2009509988A5 (https=) | ||
| KR900001683A (ko) | 피페리딘 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100803 |